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Abstract
Background: Nucleosome translocation along DNA is catalyzed by eukaryotic SNF2-type ATPases. One class of SNF2-
ATPases is distinguished by the presence of a C-terminal bromodomain and is conserved from yeast to man and plants. This
class of SNF2 enzymes forms rather large protein complexes that are collectively called SWI/SNF complexes. They are
involved in transcription and DNA repair. Two broad types of SWI/SNF complexes have been reported in the literature; PBAF
and BAF. These are distinguished by the inclusion or not of polybromo and several ARID subunits. Here we investigated
human SS18, a protein that is conserved in plants and animals. SS18 is a putative SWI/SNF subunit which has been
implicated in the etiology of synovial sarcomas by virtue of being a target for oncogenic chromosomal translocations that
underlie synovial sarcomas.
Methodology/Principal Findings: We pursued a proteomic approach whereby the SS18 open reading frame was fused to a
tandem affinity purification tag and expressed in amenable human cells. The fusion permitted efficient and exclusive
purification of so-called BAF-type SWI/SNF complexes which bear ARID1A/BAF250a or ARID1B/BAF250b subunits. This
demonstrates that SS18 is a BAF subtype-specific SWI/SNF complex subunit. The same result was obtained when using the
SS18-SSX1 oncogenic translocation product. Furthermore, SS18L1, DPF1, DPF2, DPF3, BRD9, BCL7A, BCL7B and BCL7C were
identified. ‘Complex walking’ showed that they all co-purify with each other, defining human BAF-type complexes. By
contrast,we demonstrate that human PHF10 is part of the PBAF complex, which harbors both ARID2/BAF200 and
polybromo/BAF180 subunits, but not SS18 and nor the above BAF-specific subunits.
Conclusions/Significance: SWI/SNF complexes are found in most eukaryotes and in the course of evolution new SWI/SNF
subunits appeared. SS18 is found in plants as well as animals. Our results suggest that in both protostome and
deuterostome animals, a class of BAF-type SWI/SNF complexes will be found that harbor SS18 or its paralogs, along with
ARID1, DPF and BCL7 paralogs. Those BAF complexes are proteomically distinct from the eukaryote-wide PBAF-type SWI/
SNF complexes. Finally, our results suggests that the human bromodomain factors BRD7 and BRD9 associate with PBAF and
BAF, respectively.
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Introduction
Gene expression programs determine cell identity and response
to endocrine stimuli, as has been demonstrated most dramatically
by the generation of induced pluripotent stem cells with the Oct4,
Sox2, Klf4 and c-Myc transcription factors [1]. Such epigenetic
programming involves many nucleosome remodeling activities [2].
Besides covalent nucleosome modifications such as acetylation and
methylation, a second type of nucleosome remodelling involves
translocation of nucleosomes along chromosomal DNA [3–5] as
well as the catalysis of alternative nucleosome conformations, and
even nucleosome eviction [6–8]. These nucleosome transactions
are catalyzed by SNF2 type enzymes, a group of ATPases that
belongs to the SFII ATPase superfamily that includes many
helicases [9]. The present paper is concerned with a subtype of the
nucleosome remodeling SNF2 enzymes that are uniquely
characterized by a C-terminal bromodomain, represented in yeast
by Snf2 and Sth1, in Drosophila by brahma and in humans by BRM
and BRG1.
The C-terminal bromo domain-bearing SNF2 enzymes are
found in so-called SWI/SNF multiprotein complexes and are
conserved in most eukaryotes. They are implicated in transcrip-
tional regulation and multiple DNA repair pathways [10–25].
These large multi-protein complexes consist of at least 4
evolutionarily conserved core subunits represented in man by
SMARCB1 and the SMARCA2/A4, SMARCC1/C2 and
SMARCD1/D2/D3 paralogs [26], and a large number of
ancillary subunits, some of which define SWI/SNF complex
subtypes. Interestingly, SWI/SNF complexes were identified as
biochemical factors that dramatically reduce the amount of time
required to reprogram mouse embryonic fibroblasts into iPS at the
hand of recombinant transcription factors [27], underscoring the
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importance of SWI/SNF in epigenetic programming processes
[28]. Indeed, SWI/SNF has been mapped to some 50,000 human
chromosomal sites in one cultured human cell line, demonstrating
that this protein complex is a feature of many cis-acting regulatory
elements, including DNA replication origins [29].
In mice and humans, at least 20 different SWI/SNF complex
subunits have been reported (Table 1) [10,30–43]. ‘Core’ subunits
are found in virtually all cellular SWI/SNF complexes, whilst
others define SWI/SNF complex subtypes. There are two broad
classes of SWI/SNF complexes known; BAF-type SWI/SNF
complexes (BRG1/BRM-associated factors) bear either one of
ARID1A/BAF250a or ARID1B/BAF250b, whilst PBAF (Poly-
bromo-associated BAF) complexes harbor both ARID2/BAF200
and polybromo/BAF180 subunits [38,39,44,45]. Functionally,
ARID1B/BAF250b was shown to be required to maintain ES cell
identity [46] whilst ARID1A/BAF250a is required to permit
proper ES cell differentiation with retinoic acid [47]. Furthermore,
the SMARCC variant BAF170 is expressed less upon ES cell
differentiation [43,48,49]. Similarly, the switch from one actin
related subunit, BAF53A, to its paralog BAF53B appears to play a
Table 1. Abundance of purified proteins{ in each TAP-tag preparation.
Protein alternative names polyA mRNA* TAP INI1 SS18 SS18SSX1 BCL7A BCL7C DPF2 BRD9 PHF10
BRG1 SMARCA4 5.93 0 0.303 5.337 4.440 2.039 2.290 1.662 0.141 0.984
BRM SMARCA2 1.45 0 0 1.339 0.730 0.116 0.280 0.179 0 0.028
BAF250A SMARCF1, ARID1A 1.63 0 0.027 5.692 2.079 0.379 1.766 1.485 0.027 0.027
BAF250B ARID1B, OSA1 2.04 0 0 2.728 1.540 0.179 0.638 0.315 0.028 0
BAF200 ARID2, zipzap nd 0 0.122 0 0.029 0.029 0.122 0 0 0.884
BAF180 Polybromo-1 4.36 0 0.457 0 0 0 0.248 0 0 1.769
BAF170 SMARCC2 9.25 0 1.532 2.793 2.360 0.438 1.432 1.154 0.084 1.745
BAF155 SMARCC1 6.94 0 2.981 5.813 3.467 1.239 2.043 2.831 0.080 0.468
BAF60A SMARCD1 4.01 0 0.15 3.037 3.037 0.784 2.054 1.477 0.072 0.630
BAF60B SMARCD2 7.69 0 0.719 7.161 4.080 1.762 2.875 2.384 0 0.607
BAF60C SMARCD3 3.02 0 0 1.102 0.346 0 0.346 0.16 0 0
BAF57 SMARCE1 9.97 0 0.957 11.115 5.190 1.154 3.642 3.217 0.957 1.61
BAF53A ACTL6A, ArpNß 8.37 0.233 0.110 6.305 6.305 2.511 2.511 0.874 0.369 0.52
BAF53B ACTL6B, ArpNa 1.68 0 0 0 0 0 0 0 0 0
BAF47 SMARCB1, INI1, SNF5 5.81 0 0.931 5.449 3.160 1.154 3.160 0.551 0.245 0.823
BAF45A PHF10 3.08 0 0.086 0 0 0 0 0 0 2.728
BAF45B DPF1 0.50 0 0 0 0.110 0 0.110 0 0 0
BAF45C DPF3, CERD4 0.26 0 0 0 0 0 0.105 0 0 0
BAF45D DPF2, REQ, UBID4 2.80 0 0 4.623 1.610 0.101 1.371 1.873 0 0
SS18 SYT, SSXT 3.73 0 0 9.00 9.00 0.78 0 2.16 1.000 0
SS18L1 CREST 9.92 0 0 0 0 0 0.585 0.585 0 0
BCL7A - nd 0 0 0.874 1.310 3.329 0 0.585 0.233 0
BCL7B Hom s 3 4.77 0 0 0 0.292 0 0 0 0 0
BCL7C - 4.18 0 0 0 1.783 0 11.915 0 0 0
BRD7 CELTIX-1 nd 0 0.064 0 0 0 0 0 0 0.645
BRD9 MU-RMS-40.8 0.18 0 0 0.186 0.668 0 0.089 0 4.505 0
SSX1 - nd 0 0 0 1.154 0 0 0 0 0
GLTSCR1 GSCR1 1.20 0 0 0.619 1.116 0.055 0.708 0 0 0
SRRM2 - 8.15 0 0 0 0 0 0 0 0 0
MYBBP1A p160 3.72 0 0 0 0 0 0 0 0 0
NONO NMT55, p54(nrb) nd 0.066 0 0 0.066 0 0 0 1.966 0.292
NUMA1 - 3.23 0 0 0 0 0 0 0 0.167 0
SFPQ PSF 11.42 0.199 0 0 0 0 0 0 0.624 0.528
DDX3X HLP2 12.18 0.116 0 0 0 0 0 0 10.159 0.315
DDX17 p72 11.85 0.058 0 0 0 0 0 0.058 9.578 0.136
RBM14 COAA 7.10 0 0 0 0 0 0 0 4.736 0
DDX5 p68 17.37 0 0 0 0 0 0 0.061 4.223 0.805
actin actg1 30.37 4.109 1.371 4.109 6.499 2.481 2.831 0.778 7.254 3.437
{Protein abundance is represented by the exponentially modified Protein Abundance Index [96].
*mRNA abundance was estimated from probe set fluorescence signal intensities, as recommended by Affymetrix (see Data S2).
doi:10.1371/journal.pone.0033834.t001
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key role in neuron progenitor differentiation [41,50]. Tissue
specific expression of paralogous subunits has also been reported
for the BAF60 variants [32,51–53], as well as for the minor SWI/
SNF subunits DPF1 and 3 [41,42,50].
Strikingly, multiple SWI/SNF subunits function as tumor
suppressors in man and mouse, adding a key medical dimension
to SWI/SNF research [24,54–66]. For instance: the INI1flox/flox
mouse is the most lethal tumor suppressor mouse model reported
to date [55], suggesting a decisive role for SWI/SNF in cell
proliferation control. Cell cycle roles for SWI/SNF-type complex-
es have indeed been documented in human and in model
organisms [67–78].
Another link to cancer is provided by the SS18-SSX oncofusion
proteins [79]. Synovial sarcomas are aggressive soft-tissue tumors
accounting for about ten percent of all human soft-tissue sarcomas
[80]. Characteristic for synovial sarcomas is the t(X;18)(p11.2;q11.2)
translocation which is found in over 95% of all synovial sarcoma
cases and results in the fusion of the SS18 (also called Syt) gene on
chromosome 18 with one of the highly homologous SSX genes,
SSX1, SSX2 or SSX4, on the X chromosome and consequently the
expression of SS18-SSX fusion proteins [81–84]. These transloca-
tion events are believed to be the main molecular basis of this
disease [79]. Orthologs of the SS18 protein also exists in plants.
They are positive regulator of cell proliferation in lateral organs,
such as leaves and flowers and appear to control aspects of cell
proliferation together with DNA sequence-specific GRF transcrip-
tion factors [85,86]. Mammalian SS18 has been reported to
associate with SWI/SNF chromatin remodeling complexes and to
interact with BRG1 and BRM proteins [87–90]. In order to identify
protein interactors of the SS18 and SS18-SSX proteins and to
characterize the SS18 and SS18-SSX complexes we exploited a
Tandem Affinity Purification (TAP) tagging approach combined
with mass spectrometric analysis [91].
We found SS18 to be present in BAF-class human SWI/SNF
chromatin remodeling complexes. Purification of SS18-SSX1
revealed that this oncofusion protein resides in the same
complexes. Interestingly, we detected several additional putative
SWI/SNF interactors [92–95]. Complex walking revealed the
presence of these proteins in the same BAF SWI/SNF complexes
as SS18, refining observations made by others [41,43]. Overall, we
conclude that human SS18 and its paralogue SS18l1/CREST
together with; double PHD finger factors (DPF1,-2,-3), the B-cell
CLL/lymphoma 7 protein family members (BCL7A, -B, -C) and
BRD9 are specific to BAF-class SWI/SNF complexes, whilst
BRD7 and PHF10 characterize PBAF complexes. Furthermore,
with the exception of BRD7 and BRD9, quantitative mass
spectrometry analysis demonstrates that the major proteomic
interaction partners of all these factors are SWI/SNF subunits,
indicating that they are bona fide BAF-type SWI/SNF complex
subunits.
Results
TAP-tag purification of SWI/SNF complexes
In order to define the protein complexes harboring known and
suspected human SWI/SNF subunits we generated stable human
embryonic kidney cell (Hek293) clones transduced with retroviral
TAP-tag fusion expression constructs [91]. The following eight
TAP-fusions were purified and analyzed by mass spectrometric
analysis; INI1, SS18 and its oncogenic fusion product SS18-SSX1,
BCL7A and BCL7C, DPF2, PHF10 and BRD9 (Figure 1A). The
proteomic data we have collected (Table 1, Data S1) is
schematized in Figure 1B, where the thickness of the edges reflect
co-purification efficiency [96].
INI1
INI1 is a core subunit of SWI/SNF complexes that is also
known as hSNF5, SMARCB1 or BAF47. In our hands the yield of
SWI/SNF complexes obtained with INI1TAP has consistently been
comparatively low. For instance, in most INI1TAP preparations we
detect BRG1 but not BRM, and ARID1A but not ARID1B
(Table 1). This is consistent with BRG1 and ARID1A mRNA
levels being 2–3 times that of their respective paralogs in Hek293
cells (Table 1, Data S2), a fact that is also reflected in the yields of
these paralogous subunits in all the purifications (Table 1).
Another indication that the INITAP construct is not amenable to
very high yield SWI/SNF purifications is that of all the proteins we
employed here to purify SWI/SNF complexes, only two, PHF10
and BRD7, are detected by INI1TAP, whilst INI1 was detected in
all the reciprocal purifications (Table 1).
In keeping with a role as a core SWI/SNF subunit, INI1TAP
purifications harbored both PBAF and BAF-specific SWI/SNF
subunits (Table 1, Table 2). The comparatively higher yield of the
PBAF-specific subunits ARID2 and polybromo versus the BAF-
specific ARID1A and ARID1B suggests that INI1-bearing PBAF
complexes are more preponderant than INI1-bearing BAF
complexes in Hek293 cells, in line with the higher expression
level of the PBAF-specific polybromo subunit (Table 1).
SS18 and the oncogenic SS18-SSX fusions are BAF
subunits
SS18TAP purifications yielded high levels of SWI/SNF (Table 1,
Figure 1). All known core subunits were found, consistent with
previous work [87,97]. Since both ARID1A and ARID1B but no
ARID2 nor polybromo peptides were found, SS18 appears to be
specific to both the ARID1A and ARID1B-bearing BAF-class
variants of SWI/SNF (Table 1). Furthermore, several other potential
SS18 interactors were identified, including GLioma Tumor
Suppressor Candidate Region gene 1 protein (GLTSCR1), zinc
finger protein ubi-d4 (DPF2), B-cell CLL/lymphoma 7A (BCL7A)
and bromodomain containing protein 9 (BRD9) (Table 1, Figure 1B).
Because the chromosomal translocation t(X;18)(p11.2;q11.2)
results in production of the oncogenic SS18-SSX1 protein fusion it
was of interest to compare the proteomic environments of SS18
and the SS18 oncofusions. Essentially, purification of SS18-
SSX1TAP resulted in the same set of interactors as purification of
SS18TAP, with the exception of peptides originating from the
SSX1 moiety of the oncofusion protein (Table 1). All subunits of
the SWI/SNF BAF variant complex were identified, as well as the
novel interactors GLTSCR1, DPF2 and its paralog DPF1, BRD9,
and BCL7A and its paralogs BCL7B and C (Table 1, Figure 1B).
We conclude that, similarly to SS18, the SS18-SSX1 oncofusion
protein also resides in both the ARID1A and ARID1B-bearing
BAF variants of human SWI/SNF.
DPF2 resides in BAF
DPF2, also known as ubi-d4 or Requiem, is ubiquitously
expressed and implicated in apoptosis [92]. It belongs to the d4
family which in humans consists of three paralogous genes: neuro-
d4 (DPF1), ubi-d4 (DPF2) and cer-d4 (DPF3) [98,99]. This gene
family is not present in any of the currently sequenced plant
genomes. Figure 2A shows that DPF factors harbor a conserved N-
terminal domain (Pfam14051, [100]), a central C2H2-type
Kru¨ppel zinc finger motif with potential nucleic acid binding
activity and C-terminal double paired finger PHD domains that
have been shown to mediate conditional protein-protein interac-
tions [42,101,102]. DPF1, 2, 3 and PHF10 were named BAF45A-
D [41] because they were found in biochemical SWI/SNF
preparations.
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The DPF2TAP purification results indicate that DPF2 resides
mainly in ARID1-bearing BAF complexes, since no polybromo or
ARID2 peptides were identified, whilst high confidence ARID1A
and ARID1B peptides were detected (Table 1). Furthermore, like
SS18TAP, DPF2TAP co-purified BCL7A and BRD9 as well as the
SS18 paralog, SS18l1. Association of DPF2 with SS18 was further
confirmed by co-immunoprecipitation (Figure 2C).
PHF10 resides in PBAF
PHF10 harbors two PHD domains but it is not a member of the
DPF paralog group as it lacks a central Kru¨ppel zinc finger motif,
and harbors a SAY domain that is conserved in animals but not
plants [103] (Figure 2A). In contrast to DPF2TAP, PHF10TAP was
second only to INI1TAP in its yield of the PBAF-specific subunits
ARID2 and polybromo (Table 1), demonstrating a strong
association with PBAF-class SWI/SNF complexes. None of the
BAF-associated SS18, DPF or BCL7 factors were detected in
PHF10TAP preparations, suggesting that PHF10 indeed resides in
a distinct subset of SWI/SNF complexes. Complete exclusion of
PHF10 from BAF complexes may not be the case however, since
one high confidence ARID1A-derived peptide was identified.
Whether this reflects physiological subunit exchange between
subtypes of SWI/SNF complexes or mal-assembled complexes
remains an open question.
Figure 1. Complex walking. (A) Silver-stained gels of the actual purified protein preparations that were analyzed by mass spectrometry. The
respective TAP-tag fusion proteins are designated by black triangles. Size markers (Da) are indicated for every gel. Banding patterns differ because the
gels were not all run under the same conditions. (B) Osprey interaction network [131] based on the mass spectrometry results obtained with the
material shown in panel A. Blue name labels indicate the TAP-tag fusion employed here. The thickness of the lines reflect purification yield and are
proportional to the emPAI values [96] shown on Table 1. The presence of orthologs in yeast and Drosophila genomes of the human factors that are
displayed is indicated on Table 2.
doi:10.1371/journal.pone.0033834.g001
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Notably, high confidence BRD7 peptides were detected, similar
to the INI1TAP purification (Table 1), suggesting that PHF10
forms PBAF-type SWI/SNF complexes that can harbor BRD7 but
not BRD9 since, PHF10TAP did not pull down BRD9, in contrast
to SS18TAP, SS18-SSX1TAP and BCL7CTAP which did pull down
BRD9 (Table 1, Figure 1B).
BCL7 proteins reside mainly in BAF
Similar to multiple SWI/SNF subunits, BCL7 family members
have been implicated in carcinogenesis [93,94]. The presence of
BCL7 family members in SWI/SNF complexes has been reported
before [43]. We succeeded in purifying BCL7ATAP and
BCL7CTAP-associated proteins (Table 1, Figure 1B). In both cases
and in contrast to INI1TAP and PHF10TAP, next to the core SWI/
SNF subunits we also recovered more BAF-specific ARID1A and
ARID1B subunit peptides (Table 1, Figure 1B), suggesting that
BCL7 factors are mainly subunits of BAF complexes. The
comparatively low levels of the PBAF-specific subunits in the
BCL7CTAP preparations may be due to the high levels of
BCL7CTAP in the cell line that was employed (Figure 1A) and
indicate that the distinction between BAF and PBAF complexes by
BAF subunits can be blurred operationally (Figure 1B). The
absence of the PBAF-specific SWI/SNF subunit PHF10 from both
BCL7TAP purifications strengthens the notion that BCL7 factors
mainly associate with the BAF variants of SWI/SNF, however.
Furthermore, the fact that BCL7CTAP co-purified DPF2, like
Table 2. Orthologs of known SWI/SNF complex subunits in human, fly and yeast.
Human Protein
Alternative
human names
Human
complex Drosophila melanogaster Fly complex
Saccharomyces
cerevisiae SWI/SNF
Saccharomyces
cerevisiae RSC [134]
BRG1 SMARCA4 Core brahma/CG5942 Core SNF2 STH1
BRM SMARCA2 Core brahma/CG5942 SNF2 STH1
BAF250A SMARCF1, ARID1A BAF OSA/eyelid/CG7467 BAP SWI1 -
BAF250B ARID1B, OSA1 BAF OSA/eyelid/CG7467 SWI1 -
BAF200 ARID2, zipzap PBAF BAP170/CG3274 PBAP - -
BAF180 Polybromo-1 PBAF polybromo/BAP180/CG11375 PBAP - RSC1, RSC2, RSC4
BAF170 SMARCC2 Core moira/BAP155/CG18740 Core SWI3 RSC8
BAF155 SMARCC1 Core moira/BAP155/CG18740 SWI3 RSC8
BAF60A SMARCD1 Core BAP60/CG4303 Core SWP73 RSC6
BAF60B SMARCD2 Core BAP60/CG4303 SWP73 RSC6
BAF60C SMARCD3 Core BAP60/CG4303 SWP73 RSC6
BAF57 SMARCE1 Core dalao/BAP111/CG7055 Core - -
BAF53A ACTL6A, ArpNb Core BAP55/CG6546 Core ARP7 & ARP9 ARP7 & ARP9
BAF53B ACTL6B, ArpNa Core ? ARP7 & ARP9 ARP7 & ARP9
BAF47 SMARCB1, INI1, SNF5 Core SNR1/CG1064 Core SNF5 SFH1
BAF45A PHF10 PBAF e(y)3/SAYP/CG12238 PBAP - -
BAF45B DPF1 BAF d4/CG2682 ? - -
BAF45C DPF3, CERD4 BAF d4/CG2682 - -
BAF45D DPF2, REQ, UBID4 BAF d4/CG2682 - -
SS18 SYT, SSXT BAF CG10555 ? - -
SS18L1 CREST BAF CG10555 - -
BCL7A - BAF BCL7-like/CG17252 ? - -
BCL7B Hom s 3 BAF BCL7-like/CG17252 - -
BCL7C - BAF BCL7-like/CG17252 - -
BRD7 CELTIX-1 PBAF CG7154 ? - -
BRD9 MU-RMS-40.8 BAF CG7154 - -
actin actg1 actin actin actin
RTT102 RTT102
SWP82 NPL6
HTL1
LDB7
RSC3
RSC30
RSC58
RSC9
SNF6
doi:10.1371/journal.pone.0033834.t002
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BCL7ATAP, as well as the DPF2 paralogs DPF1 and DPF3 suggest
that these two DPF2 paralogs also associate with BAF complexes.
Indeed, co-purification of DPF1 and DPF3 parallels the
purification results obtained with SS18-SSX1TAP (see above)
again pointing towards the BAF variants of SWI/SNF. Finally, like
DPF2TAP, BCL7CTAP also pulled down SS18l1 (Table 1,
Figure 1B), a paralog of SS18 also known as CREST which has
previously been linked physically to ARID1B [104], again
strengthening the conclusion that BCL7A and BCL7C are mainly
subunits of the BAF variants of SWI/SNF complexes. Interest-
ingly, orthologs of BCL7 can only be found in sequenced animal
genomes.
BRD9 associates with BAF
A well established function of bromodomains is to recognize
specific acetylated lysines. The paralogous catalytic subunits of
SWI/SNF, BRG1 and BRM harbor one C-terminal bromodo-
main that is closely related to the six bromodomains of polybromo,
but quite distinct from the bromodomains of BRD7 and BRD9
[105–107].
A FLAG-BRD7 fusion has been reported to purify PBAF
complexes [43]. We were not able to successfully perform
BRD7TAP purifications (data not shown). However, BRD9TAP
did yield significant mass spectrometry results (Table 1, Figure 1).
BRD9TAP yielded peptide hits for at least one paralog of each core
SWI/SNF subunit and, contrary to what was reported for BRD7
[43,108], the presence of high confidence ARID1A and ARID1B
peptides indicates inclusion of BRD9 in BAF complexes. This
notion is buttressed by the presence of SS18 and BCL7C amongst
the proteins co-purifying with BRD9TAP (Table 1, Figure 1, Data
S1). Association of BRD9 with SS18TAP was further confirmed by
co-immunoprecipitation (Figure 2C).
We quantified our mass spectrometry data on the basis of the
exponentially modified protein abundance index (emPAI, Table 1,
Figure 1) and this revealed that BRD9TAP did not efficiently purify
SWI/SNF (Table 1), in keeping with our gel electrophoresis
analysis (Figure 1A). The major factors we identified in our BRD9
preparation are the DEAD box ATP-dependent RNA helicases
DDX3X, DDX5 and DDX17 and the RNA binding factor
RBM14/COAA (Table 1). Since Emerson and co-workers
reported substantially higher ATPase activity in their BRD7
preparations than predicted by BRG1/BRM content, it may
perhaps be that BRD7 also co-purifies the DEAD box RNA
helicases DDX3X, DDX5 and/or DDX17 [43,109,110]. Simi-
larly, RBM14/COAA is a nuclear receptor co-activator [111].
Furthermore, RBM14/COAA has previously been reported to
associate with SS18 in yeast two hybrid assays [112,113].
However, arguing against a direct interaction between SS18 and
RBM14, we did not detect RBM14/COAA when SS18TAP or
SS18-SSX1TAP associated factors were purified (Table 1,
Figure 1B).
Putative BAF associated proteins
Crabtree and colleagues [49] published a list of putative novel
BAF-associated proteins which we have monitored in this data set.
Hence, we also detected GLTSCR1 in our SWI/SNF complex
preparations (Table 1). GLTSCR1 is a candidate tumor
suppressor gene for gliomas [114]. As we detected GLTSCR1 in
four of five BAF purifications (Table 1), our results support the
notion that GLTSCR1 is a BAF-associated factor, but this will
need to be confirmed directly.
Of the other putative novel BAF-associated proteins, we could
detect NONO and its binding partner SFPQ [115,116], however,
at levels that were not much higher than in control purifications
(Table 1). Thus, although our data do not exclude an interaction
with SWI/SNF, more experimental evidence is needed on this
front. Finally, the proposed putative BAF-associated factors
NUMA1, SRRM2 and MYBBP1A [49] were not detected in
any of our SWI/SNF purifications (Table 1), suggesting weak
biochemical association with SWI/SNF in the ‘293’ human
embryonic kidney cell line, if any.
Discussion
Paralogous human SWI/SNF subunits are known to be
expressed in tissue and signal specific fashion, generating
alternative SWI/SNF complex configurations that can cooperate
Figure 2. SS18 and the animal-specific SWI/SNF subunits. (A)
Domain organization of the human proteins DPF1,-2,-3; PHF10; SS18
and its paralog SS18l1/crest; and BCL7A,-B,-C. We note that while
CG2682, the Drosophila melanogaster ortholog of DPF2 (Table 2), lacks
the C2H2 domain, this domain is present in the Tribolium ortholog
D6WFQ9_TRICA [125,132,133], suggesting conservation of this domain
in protostome and in deuterostome animals (B) Co-immunoprecipita-
tion of SS18-SSX1MYC by antibodies directed against human BRM. (C)
Co-immunoprecipitation of SS18MYC by antibodies directed against
DPF2 and BRD9.
doi:10.1371/journal.pone.0033834.g002
SS18, DPF2 and BCL7 Define Human BAF Complexes
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33834
with transcription factor networks to coordinate cell proliferation
and differentiation. Here, we focus on SWI/SNF subunits that are
absent from yeast but conserved in animals and plants (SS18) or
only in animals (DPF, BCL7 and PHF10) (Table 2).
Essentially there are two types of human SWI/SNF complexes
[32,44]; those that harbor the polybromo/BAF180 and ARID2/
BAF200 subunits (PBAF-class) and those that harbor either
ARID1A/BAF250a or ARID1B/BAF250b (BAF-class) [117]. A
similar bi-partition exists in Drosophila melanogaster except that there
is only one ARID1 ortholog, namely OSA [118,119]. Similarly,
the fly genome only encodes one ortholog of the mammalian
SMARCC (CG18740/moira) and of BRD7/9 (CG7154), SS18
(CG10555), DPF2 (CG2682/d4) and BCL7 (CG17252/BCL7-
like) protein coding genes (Table 2).
Our mass spectrometry analysis of affinity tag-mediated protein
complex purifications confirms bipartition of SWI/SNF complexes
in BAF and PBAF-class complexes. We demonstrate here that the
paralogous cancer-related minor SWI/SNF subunits DPF1, -2, -3;
BCL7A, -B, -C; and SS18 and SS18L1 reside in BAF-class human
SWI/SNF complexes and, that PHF10 marks PBAF SWI/SNF
complexes. Moreover, because quantitative analysis indicates that
the chief interaction partners of PHF10, DPF2, SS18, SS18-SSX1,
BCL7A and BCL7C are the other SWI/SNF subunits, we
speculate that they exert their molecular action through their
respective SWI/SNF complexes. It remains to be seen indeed to
what extent our results, which were obtained in one human cell
line, can be extrapolated to other cell types and even other
organisms. Considering the congruence between our data and a
recent studies on Drosophila SAYP [120] and a large scale
proteomic survey of nuclear receptor co-activators [121], we
believe they can. Moreover, there may be more as yet
‘undiscovered’ human SWI/SNF subunits, such as the putative
GLTSCR1 subunit [49], and these may also be present in our data
sets (Data S1), which can be mined by interested investigators.
Since we could not detect notable differences between SS18 and
its oncogenic fusion products at the proteomic level, the oncogenic
activity of the SS18-SSX fusions may have to be sought either at
the level of SWI/SNF (dis)assembly dynamics, post-translational
modifications or an affinity for specific genomic loci [42,106,122],
although it is formally possible that the SS18-SSX oncofusion
proteins undergo different proteomic interactions in the elusive
synovial sarcoma precursor cell type than those we detected in
Hek293 cells [123].
Interestingly, we detected the bromodomain proteins BRD7 and
BRD9 in our SWI/SNF preparations. The fly protein CG7154 is
that organism’s sole BRD7/BRD9 ortholog. It will be interesting to
determine whether it associates with the fly brahma SNF2 ATPase,
and if so, whether it is specific to the BAP or PBAP fly equivalents of
BAF and PBAF. In humans, BRD7 appears to promote cellular
senescence [108,124], and, in line with our results, it has convincingly
been linked to the PBAF complex [43]. On the other hand, our data
make a novel link between BRD9 and the BAF complex defined by
SS18, DPF and BCL7, since we recovered it when BCL7CTAP,
SS18TAP and the SS18-SSX1TAP were used as affinity bait and since
in the reciprocal experiment, BRD9TAP purifications contained SS18
and BCL7A. We note however that BRD9TAP did not efficiently pull
down BAF proteins in our experimental set-up (Figure 1A). Whether
this reflects a status as a minor though BAF-specific subunit or a
technical limitation is an open question.
Altogether, this work demonstrates that paralogs of SS18, BCL7
and DPF factors, which can be found in both protostome [125])
and deuterostome animals (Table 2), together define a novel class
of BAF-type SWI/SNF complexes that is restricted to the animal
lineage. Finally, our data indicate that PHF10 versus DPF1, -2, -3
respectively mark PBAF versus BAF-type SWI/SNF complexes in
a mutually exclusive fashion.
Methods
Constructs
Tandem Affinity Purification (TAP) constructs were generated by
PCR using the oligomers indicated in parentheses and cloned into the
XhoI and EcoRI restriction sites in the retroviral expression vector
pZXN, whereby the TAP-tag sequence was fused to the coding
sequences at their N-terminus [91]. SS18 (isoform 2, cgtactGAATT-
CATGTCTGTGGCTTTCGCGG, tgacttCTCGAGTCACTGC-
TGGTAATTTCCATACT) and SS18-SSX1 (cgtactGAATTCA-
TGTCTGTGGCTTTCGCGG, tgtcatCTCGAGTTACTCGTC-
ATCTTCCTCAGGGT) coding sequence were amplified by PCR
from pIRES2 vectors [126]. DPF2 (cgtatcGAATTCATGGCG-
GCTGTGGTGGAGAAT, tgtcttCTCGAGTCAAGAGGAGTT-
CTGGTTCTGGTA), BCL7C (cgtatcGAATTCATGGCCGGC-
CGGACTGTA, tgtcttCTCGAGTCAGGGGTCAGGGGCATT-
T), BRD9 (atacttGAATTCATGAAGGGATACCAAAGTCTTG-
TATTC, tactatCTCGAG TTAGGTCTTGGCAGAGGCCGCA)
and PHF10 (gaattcGAATTCATGCTTCAAGAACAAGTCAGT-
G, aagcttAAGCTTTTATCCCTCTTTGCTGTTTTTCC, cloned
into pBSIISK+ cut by the same enzymes and then released using SalI
and EcoRI and further subcloned) coding sequences were amplified
from cDNA clones (RZPD or OriGene). BCL7A (isoform 2,
ttacttCAATTGATGTCGGGCAGGTCGGGT, tacttaGTCGAC-
CTACATCTCTTCGGAGTTTTGTTG) was amplified from
cDNA of Hek293 cells. INI1 (atacttGAATTCATGAAGGGATAC-
CAAAGTCTTGTATTC, tactatCTCGAGTTAGGTCTTGGC-
AGAGGCCGCA) was amplified from pUHD-10-3-INI1 [127].
The retroviral vector pZXN is derived from the pZOME-1N vector
(Euroscarf) and contains a TAP-tag consisting of one protein A
domain followed by two tobacco etch virus cleavage sites (TEV) and
then either a MYC epitope (GCCGGCAAGCCCCGGCATAT-
GAATTTAATGGAGCAGAAGCT TATCAGCGAGGAGGAC-
CTGGGCGGGGAATTC) or, in the case of PHF10, a TY1 epitope
(GCCGGCGCCGATGCCGGCAAGCCCCGGCA TAGGACC-
GGTGAGGTGCACACCAACCAGGACCCCCTGGACGAAT-
TC) 59 of the EcoRI cloning site. Every clone was verified by DNA
sequencing.
Cell culture and stable cell lines
Human Embryonic Kidney (Hek293, ATCC CRL-1573) and
phoenix cells were grown in Dulbecco’s modified Eagles medium
(Invitrogen) supplemented with 10% FCS, penicillin 100 mg/ml and
streptomycin 100 U/ml (Invitrogen) at 37uC in 5%CO2. Retroviral
stable cell lines were generated as previously described [91]. Briefly,
phoenix amphotropic packaging cells were transfected with 20 mg
retroviral plasmid pZXN-SS18, pZXN- SS18-SSX1, pZXN- SS18-
SSX2, pZXN-DPF2, pZXN-BRD9, pZXN-BCL7A, pZXN-
BCL7C, pZXN-PHF10 or pZXN-INI1 after which Hek293 cells
were transduced with virus containing supernatant in two infectious
rounds of 24 hours in the presence of 8 mg/ml polybrene. Clones
were selected with 1 mg/ml puromycin and tested for recombinant
protein expression. Transduction of SS18 and SS18-SSX TAPtag
fusions in the syo-1 synovial sarcoma cell line [128] were not
successful (data not shown). Since Hek293 cells expressed the
transduced transgenes efficiently and could be expanded as desired,
we performed our study with this cell line.
Tandem Affinity Purification
Tandem Affinity Purification was performed as previously
described in detail [91]. Shortly, whole cell extracts from cell lines
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expressing TAP-tagged proteins were incubated with IgG
sepharose beads (Pharmacia). After TEV cleavage the TEV
eluates were pre-cleared with protein A beads and used for
immunoprecipitation with anti-MYC or anti TY1 epitope
antibodies. Proteins were eluted from the beads by peptide
elution, loaded on a SDS-PAGE gel and visualized by silver
staining. The same protocol was employed for all the purifications
reported here.
Co-immunoprecipitation
Co-immunoprecipitations were performed on TEV cleavage
eluates obtained as described above, using antibodies directed
against BRM (Abcam 15597), DPF2 (Aviva systems biology
ARP33221_P050) or BRD9 (Aviva systems biology ARP34803_
T200), under the same conditions as the anti-MYC or TY1
immunoprecipitations in the TAPtag purification protocol. The
immunoprecipitated proteins were separated by SDS-PAGE,
transferred onto nylon filters and probed with anti-MYC anti-
bodies, which recognize the transduced SS18-SSX1 (Figure 2B) or
SS18 (Figure 2C) proteins.
Mass spectrometry
The silver stained gel lanes were cut into small pieces. After
reduction and alkylation the proteins were trypsin (Promega)
digested and extracted from the gel using trifluoroacetic acid
(TFA). Peptides were sequenced using a nano-high-pressure liquid
chromatography Agilent 1100 nanoflow system connected online
to a 7-Tesla linear quadrupole ion-trap Fourier transform (FT)
mass spectrometer (Thermo Electron, Bremen, Germany) essen-
tially as described previously [129]. MSquant software package
(http://www.msquant.sourceforge.net) was used to parse the raw
files and for generation of peak lists. The mascot algorithm was
used to identify the proteins [130]. Exponentially Modified Protein
Abundance Index (emPAI) factors were calculated as described
previously [96], using high confidence peptides (Data S1,
MASCOT score$20, delta$5, error#5; 400–6000 Da).
Expression profiling
Expression profiling was performed on four Hek293 polyA
mRNA samples by microarray analysis using Affymetrix human
exon array 1.0 ST according to manufacturer instructions
(Data S2).
Supporting Information
Data S1 Mass spectrometry results, including; accession num-
bers, short protein descriptions, peptide sequences, associated
Mascot score, peptide delta score and absolute calibrated mass
relative error.
(XLS)
Data S2 Quadruplate polyA mRNA expression profile of
Hek293 cells determined with the Affymetrix human exon array
1.0 ST platform.
(XLS)
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